EPS for ZIOPHARM Oncology Inc. (ZIOP) Expected At $-0.13; Williams Sonoma (WSM)’s Sentiment Is 1.45

October 29, 2017 - By Peter Erickson

Analysts expect ZIOPHARM Oncology Inc. (NASDAQ:ZIOP) to report $-0.13 EPS on November, 8.They anticipate $0.02 EPS change or 18.18% from last quarter’s $-0.11 EPS. After having $-0.13 EPS previously, ZIOPHARM Oncology Inc.’s analysts see 0.00% EPS growth. The stock increased 6.47% or $0.29 on October 27, reaching $4.77. About 2.28M shares traded or 79.53% up from the average. ZIOPHARM Oncology Inc. (NASDAQ:ZIOP) has risen 1.75% since October 29, 2016 and is uptrending. It has underperformed by 14.95% the S&P500.

Williams-Sonoma, Inc. is a multi-channel specialty retailer of products for the home. The company has market cap of $4.46 billion. The Firm operates retail stores in the United States, Canada, Puerto Rico, Australia and the United Kingdom. It has a 15.1 P/E ratio. It operates through two divisions: e-commerce and retail.

Blackhill Capital Inc holds 37.4% of its portfolio in Williams-Sonoma, Inc. for 4.03 million shares. Hutchinson Capital Management Ca owns 348,411 shares or 4.79% of their US portfolio. Moreover, Holowesko Partners Ltd. has 3.35% invested in the company for 1.02 million shares. The Minnesota-based Minneapolis Portfolio Management Group Llc has invested 2.88% in the stock. Reik & Co. Llc, a New York-based fund reported 177,329 shares.

The stock decreased 0.08% or $0.04 on October 27, reaching $52.42. About 1.02 million shares traded. Williams-Sonoma, Inc. (WSM) has risen 0.69% since October 29, 2016 and is uptrending. It has underperformed by 16.01% the S&P500.

Analysts await Williams-Sonoma, Inc. (NYSE:WSM) to report earnings on November, 16. They expect $0.84 EPS, up 6.33% or $0.05 from last year’s $0.79 per share. WSM’s profit will be $71.47M for 15.60 P/E if the $0.84 EPS becomes a reality. After $0.61 actual EPS reported by Williams-Sonoma, Inc. for the previous quarter, Wall Street now forecasts 37.70% EPS growth.

Ratings analysis reveals 25% of Williams-Sonoma’s analysts are positive. Out of 4 Wall Street analysts rating Williams-Sonoma, 1 give it “Buy”, 0 “Sell” rating, while 3 recommend “Hold”. The lowest target is $52.0 while the high is $61.0. The stock’s average target of $56.50 is 7.78% above today’s ($52.42) share price. WSM was included in 4 notes of analysts from October 26, 2016. On Wednesday, January 4 the stock rating was initiated by Loop Capital with “Hold”. The firm has “Neutral” rating by Robert W. Baird given on Monday, November 14. Telsey Advisory maintained Williams-Sonoma, Inc. (NYSE:WSM) on Friday, November 18 with “Outperform” rating. The firm has “Perform” rating given on Wednesday, October 26 by Oppenheimer.

ZIOPHARM Oncology, Inc. is a biopharmaceutical company, which is seeking to develop, acquire and commercialize, on its own or with partners, a portfolio of cancer therapies that address unmet medical needs. The company has market cap of $677.16 million. The Firm is focused on developing products in immuno-oncology that employ gene expression, control and cell technologies to deliver cell- and viral therapies for the treatment of cancer and graft-versus-host-disease. It currently has negative earnings. It has developed an adenoviral vector, Ad-RTS-IL-12, which is administered intra-tumorally under the control of the RheoSwitch Therapeutic System expression platform.